This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

HIV disease resulting in multiple infections다발감염을 유발한 인체면역결핍바이러스병

Contents and key points
ItemDetails
A. Classification codesICD-10: B20.7 (HIV disease resulting in multiple infections) | Special Copayment Reduction: V103 (severe intractable disease, 5 years)
B. SynonymsHIV disease resulting in multiple infections; AIDS with multiple opportunistic infections
C. Adult onsetLikelihood of adult onset: very high — HIV infection itself occurs at all ages, but multiple opportunistic infections due to immunosuppression appear mainly at the AIDS stage, years after infection, and are most commonly diagnosed in adults (especially early adulthood to middle age). Multiple infections tend to occur after the CD4+ T-cell count falls below 200/μL, and the risk is high in patients who have not started antiretroviral therapy (ART) or in whom treatment has failed.
1. History1981 CDC report of Pneumocystis pneumonia in gay men → AIDS definition established → HIV officially named in 1986 → introduction of HAART in 1996 sharply reduced the incidence of opportunistic infections → patterns of multiple infection are changing in the current ART era.
2. CausesA state in which immune function is reduced by destruction of CD4+ T cells by HIV-1 or HIV-2, leading to simultaneous or sequential infection with many pathogens such as bacteria, fungi, viruses, and parasites.
3. GeneticsHIV is not a hereditary disease. Host polymorphisms such as the CCR5 Δ32 mutation and HLA-B*57:01 influence HIV susceptibility and the prognosis of opportunistic infections. Viral genetic diversity (HIV-1 group M subtypes A–K) influences virulence and treatment response.
4. General epidemiologyUNAIDS 2024: about 39.9 million people living with HIV worldwide. Multiple infections occur in patients not treated with ART. Korea has about 20,000 cumulative infected individuals and about 1,000 new cases per year. The incidence of multiple infections has decreased with the expansion of ART.
5. PathophysiologyHIV destruction of CD4+ T cells → collapse of cell-mediated immunity → opportunistic infections at CD4 <200/μL → simultaneous infection with multiple pathogens possible. Immune reconstitution inflammatory syndrome (IRIS) also contributes to patterns of multiple infection.
6. SymptomsFever, weight loss, night sweats, chronic diarrhea, cough, dyspnea, oral and esophageal lesions, and neurological symptoms occur in combination. The specific symptoms of each opportunistic infection appear simultaneously, making the clinical picture complex.
7. SignsWeight loss, lymphadenopathy, oral candidiasis, retinal lesions, skin lesions (EBV-associated oral leukoplakia), low CD4+ count, high plasma viral load, multiple abnormal findings on imaging.
8. ScreeningHIV antibody/antigen screening test (4th generation), CD4+ T-cell count, HIV RNA viral load. Regular screening of high-risk groups (sexual exposure, injection drug users, transfusion recipients).
9. DiagnosisAfter HIV confirmation, microbiological, serological, and imaging diagnosis of each opportunistic infection in parallel. Assessment of the likelihood of opportunistic infection according to CD4 level. Culture of individual pathogens, antigen testing, PCR, and tissue biopsy applied.
10. TreatmentEarly ART initiation (at any CD4 level) is fundamental. Specific anti-infective treatment for each opportunistic infection in parallel. Chemoprophylaxis for opportunistic infections (PCP prophylaxis: TMP-SMX, etc.). Management of drug interactions.
11. PrognosisMortality from multiple infections at the AIDS stage before ART was very high. After ART, opportunistic infections fall sharply with CD4 recovery, and long-term survival is possible. Early treatment initiation is the key prognostic determinant.
12. PreventionEarly ART initiation and continuation, chemoprophylaxis such as TMP-SMX, safe sex, PrEP use, no needle sharing, screening of transfused blood.
13. ReferencesUNAIDS 2024 Global AIDS Update and 9 others

1. History

The history of HIV/AIDS began in 1981 when the US Centers for Disease Control and Prevention (CDC) reported Pneumocystis carinii pneumonia and unusual immune suppression in five gay men in Los Angeles. In the same year, cases of Kaposi's sarcoma and other opportunistic infections were reported, forming the clinical concept of acquired immunodeficiency syndrome (AIDS). This immunodeficiency state of unknown cause spread rapidly, and in 1982 occurrence was also confirmed in hemophilia patients and transfusion recipients, making clear that AIDS is a blood-borne infection.

In 1983, the team of Luc Montagnier at the Pasteur Institute in France isolated a retrovirus from the lymph nodes of AIDS patients, and the team of Robert Gallo at the US National Cancer Institute subsequently discovered the same virus. In 1986 this virus was officially named Human Immunodeficiency Virus (HIV) by an international committee. HIV-1 and HIV-2 were subsequently distinguished, and HIV-1 was confirmed as the main cause of the global pandemic.

Early AIDS was a fatal disease characterized by multiple opportunistic infections. In the 1980s, with no effective treatment, various opportunistic infections such as Pneumocystis pneumonia, cytomegalovirus (CMV) retinitis, cryptococcal meningitis, Mycobacterium avium complex (MAC) infection, and toxoplasmosis led patients to death. In 1987 zidovudine (AZT) was approved as the first antiretroviral drug, but monotherapy had limited effect owing to the development of resistance.

The turning point in the clinical picture of AIDS with multiple infections was the introduction in 1996 of highly active antiretroviral therapy (HAART, now ART). This combination of multiple drugs effectively suppresses HIV replication and restores the CD4+ T-cell count, dramatically reducing the incidence of opportunistic infections. After ART, mortality from AIDS-related multiple infections decreased by more than 80% in developed countries, and HIV infection came to be regarded as a chronically manageable disease. However, in low- and middle-income countries, multiple infections remain a leading cause of death owing to problems with ART access.

In Korea, the number of infected individuals has increased continuously since the first HIV-infected individual was reported in 1985. Initially, infection occurred in transfusion recipients and hemophilia patients, and sexual transmission later became the main route. The AIDS Prevention Act was enacted in 1991, a management system for infected individuals was established from 1994, and insurance coverage of ART was expanded from the early 2000s. At present, the number of patients at the AIDS stage with multiple infections is decreasing in Korea, but there are still cases who present for the first time in a state of multiple opportunistic infections when diagnosed late.


2. Causes

The cause of HIV infection resulting in multiple infections, designated by the B20.7 code, is progressive immunosuppression caused by HIV-1 or HIV-2. HIV is transmitted mainly through sexual contact, exposure to contaminated blood and blood products, and vertical transmission (mother-to-child). Once HIV enters the body, it uses the CD4 receptor and a co-receptor (CCR5 or CXCR4) to infect mainly CD4+ T lymphocytes, macrophages, and dendritic cells.

Routes of HIV transmission

Worldwide, sexual transmission is the most common, and the transmission risk is especially high in anal intercourse (about 1.4% for the receptive partner and about 0.08% per act for the insertive partner). Needle sharing among injection drug users carries a high transmission risk, at about 0.63% per sharing. Vertical transmission (pregnancy, delivery, breastfeeding) has a transmission rate of about 15–45% without ART. In developed countries, transfusion-related transmission has become almost nonexistent owing to testing of transfused blood, but the risk still exists in some regions.

Pathogens of multiple infections

The pathogens of opportunistic infections that occur as the CD4+ T-cell count decreases are diverse. At CD4 counts below 200/μL, Pneumocystis jirovecii, Toxoplasma gondii, Cryptosporidium, and Cystoisospora belli are common. At CD4 counts below 100/μL, deep infections caused by Cryptococcus neoformans, CMV, Mycobacterium avium complex (MAC), and Candida increase. The B20.7 code applies when two or more of these pathogens occur simultaneously or within a short period.

Factors promoting multiple infections

Not starting ART or stopping treatment, drug-resistant HIV infection, poor treatment adherence, malnutrition, comorbid diseases (tuberculosis co-infection, chronic hepatitis B and C), and drug abuse raise the risk of multiple infections. In developing countries, tuberculosis is the most common co-pathogen of opportunistic infection in HIV-infected individuals, and tuberculosis and other opportunistic infections often occur simultaneously.


3. Genetics

HIV/AIDS is an infectious disease and not a hereditary disease. However, host genetic factors markedly influence HIV susceptibility, the rate of disease progression, the pattern of opportunistic infections, and the response to ART.

CCR5 Δ32 mutation

CCR5 is the main co-receptor of HIV-1 M-tropic virus. Homozygotes (homozygous Δ32/Δ32) for the CCR5 Δ32 mutation, a 32-base-pair deletion in the CCR5 gene, have strong resistance to HIV-1 infection. Heterozygotes (heterozygous Δ32/+) have AIDS progression delayed by about 2 years. This mutation occurs at a frequency of about 1% in northern European whites but is very rare in African and Asian populations. The CCR5 Δ32 mutation became the theoretical basis for hematopoietic stem cell transplantation for AIDS treatment (the case of the Berlin patient, Timothy Ray Brown).

HLA genotype

HLA-B*57:01 and HLA-B*27:05 are overrepresented in HIV long-term non-progressors (LTNP), and these HLA molecules are known to effectively present immunodominant epitopes of the HIV Gag protein to CD8+ T cells, suppressing viral replication. In contrast, HLA-B*35 is associated with rapid AIDS progression. HLA polymorphisms also influence the immune response to the pathogens of opportunistic infections, so certain HLA types cause differences in vulnerability to some opportunistic infections (CMV, MAC, etc.).

Other host genes

Gene polymorphisms of innate immune restriction factors such as TRIM5α (tripartite motif-containing protein 5), APOBEC3G, and BST-2 (tetherin) affect the efficiency of restricting HIV replication. Cytokine gene polymorphisms such as IL-10, TNF-α, and IFN-γ influence the level of immune activation and the tendency to develop opportunistic infections. Through GWAS (genome-wide association studies), many loci associated with HIV susceptibility, such as HCP5 and PSORS1C1, have been identified.

HIV viral genetics

HIV-1 is classified into groups M (main), N, O, and P, and group M has several subtypes from A to K. Subtype B predominates in North America and Europe, and subtype C is most common in sub-Saharan Africa and South Asia. Differences in subtype influence viral transmissibility, virulence, and patterns of drug resistance. In addition, circulating recombinant forms (CRFs) are prevalent in various regions.


4. General epidemiology

According to the 2024 UNAIDS report, there are about 39.9 million people living with HIV worldwide, with about 1.3 million new infections and about 630,000 AIDS-related deaths per year. Multiple infections at the AIDS stage occur mainly in regions where ART is not available, in late-diagnosed patients, and in patients who stopped ART.

Epidemiology by region

Sub-Saharan Africa accounts for about 65% of HIV infections worldwide, and in this region tuberculosis, cryptococcal meningitis, isosporiasis, and CMV infection are the main AIDS-defining opportunistic infections. In Southeast Asia, tuberculosis co-infection and Pneumocystis pneumonia are common. In developed countries, the occurrence of multiple infections has decreased greatly since ART, but it still occurs in socioeconomically vulnerable groups, drug users, and groups with poor access to health care.

Epidemiology in Korea

According to the 2024 KDCA report, there are about 20,000 cumulative HIV-infected individuals in Korea, with about 1,000 new cases per year. It is known that more than about 30% of HIV-infected individuals in Korea are first diagnosed at the AIDS stage with a CD4+ T-cell count below 200/μL, so diagnostic delay is a major risk factor for multiple infections. Reported major opportunistic infections include Pneumocystis pneumonia, oral candidiasis, tuberculosis, cryptococcal meningitis, and toxoplasma encephalitis.

Temporal trends in multiple infections

Before the introduction of ART in the mid-1990s, most AIDS patients died of multiple opportunistic infections. After the introduction of ART, the incidence of AIDS-defining opportunistic infections decreased by about 80–90% in developed countries. However, at the global level, multiple infections remain a major problem owing to regional disparities in ART coverage. The WHO's "95-95-95" target (95% of infected individuals diagnosed, 95% of those diagnosed receiving ART, and 95% of those treated achieving viral suppression) aims to end AIDS by 2030.


5. Pathophysiology

Multiple infections in B20.7 are based on progressive collapse of cell-mediated immunity by HIV. HIV infects CD4+ T cells, macrophages, and dendritic cells and destroys them or causes functional impairment, resulting in loss of the ability to defend against diverse pathogens.

Mechanism of CD4+ T-cell destruction

HIV uses reverse transcriptase to reverse transcribe RNA into DNA, which is then integrated into the host genome (provirus). During viral replication, CD4+ T cells continuously decline through cell death (apoptosis), cytolysis, pyroptosis, and so on. In addition, the immune response in which HIV-specific CD8+ cytotoxic T lymphocytes (CTLs) eliminate infected cells also contributes to the loss of CD4+ T cells. In the long term, as the regenerative capacity of CD4+ T cells is exhausted, the absolute count gradually declines.

Relationship between level of immunosuppression and opportunistic infections

The risk of opportunistic infection according to the CD4+ T-cell count is well established. Below a CD4 count of 500/μL, oral candidiasis and reactivated herpes zoster increase. Below CD4 200/μL, Pneumocystis pneumonia, disseminated histoplasmosis, and coccidioidomycosis are risks. Below CD4 100/μL, cryptococcal meningitis, CMV retinitis, toxoplasma encephalitis, and progressive multifocal leukoencephalopathy (PML) occur. Below CD4 50/μL, the risk of MAC bacteremia and disseminated CMV infection is very high. Multiple infection is a state in which these pathogens occur simultaneously or sequentially in patients with an extremely low CD4.

Immune reconstitution inflammatory syndrome (IRIS)

IRIS is an excessive inflammatory response to previously suppressed opportunistic pathogens that occurs as CD4+ T cells recover rapidly after ART initiation. IRIS appears within weeks to months after ART initiation as fever, worsening of an existing infection, or unmasking of a new infection. IRIS can further complicate the clinical picture of multiple infections, and IRIS associated with tuberculosis, cryptococcus, and MAC is most common.


6. Symptoms

The clinical symptoms of HIV disease resulting in multiple infections (B20.7) vary widely according to the combination of opportunistic pathogens involved. Because the symptoms of the individual opportunistic infections overlap, the clinical picture is complex, and it may be difficult to determine which symptom is attributable to which pathogen.

Systemic symptoms

High fever (especially prolonged fever lasting several weeks or more, FUO pattern), severe weight loss (10% or more within 1 month), night sweats, and extreme fatigue are common to patients with multiple infections. These systemic symptoms alone make it hard to identify which opportunistic infection is the cause.

Respiratory symptoms

In Pneumocystis pneumonia, progressive dyspnea, nonproductive cough, and fever are characteristic, accompanied by hypoxemia that worsens on exertion. CMV pneumonia presents as interstitial pneumonia. Lung involvement by MAC is also possible, and hemoptysis and chronic cough are added when tuberculosis co-infection is present. When multiple pulmonary pathogens are involved at the same time, respiratory failure can progress rapidly.

Gastrointestinal symptoms

Chronic diarrhea (Cryptosporidium, CMV, MAC enteritis, Isospora), dysphagia or odynophagia (Candida esophagitis, CMV esophagitis, herpes esophagitis), abdominal pain, and nausea and vomiting are common. When gastrointestinal symptoms are due to multiple pathogens, they lead to severe malnutrition and dehydration.

Neurologic symptoms

Headache, fever, nuchal rigidity (cryptococcal meningitis), focal neurological deficits and seizures (toxoplasma encephalitis, PML, CMV encephalitis), progressive cognitive decline (HIV-associated neurocognitive disorder, CMV encephalitis), and visual loss (CMV retinitis) may appear in combination.

Skin and mucosal symptoms

Multiple skin and mucosal lesions may appear simultaneously, such as oral candidiasis (white pseudomembrane), EBV-associated oral hairy leukoplakia, extensive herpes lesions, Kaposi's sarcoma skin lesions, and telangiectasia.


7. Signs

The physical signs and test findings of multiple-infection HIV disease are diverse and complex, reflecting multiple opportunistic infections.

Physical findings

Generalized wasting (cachexia), generalized lymphadenopathy, white pseudomembranes of oral candidiasis, oral hairy leukoplakia (white corrugated lesions on the lateral tongue), herpes lesions (oral, perianal, genital), cutaneous Kaposi's sarcoma (purple and magenta skin nodules), CMV retinitis findings on fundus examination (pizza-pie appearance), nuchal rigidity (cryptococcal meningitis), and focal neurological signs (opportunistic brain infection) may appear in combination.

Test findings

Immunological indicators: markedly decreased CD4+ T-cell count (usually <200/μL, often <50/μL in multiple infections), inverted CD4/CD8 ratio (normal >1, <0.5 as HIV progresses). Highly elevated HIV RNA viral load (about 105–106 copies/mL in untreated AIDS stage). Hematological abnormalities: anemia (chronic inflammation, MAC bone marrow involvement), leukopenia, thrombocytopenia (immune-mediated destruction or bone marrow involvement). Biochemical abnormalities: elevated LDH (sensitive but nonspecific in PCP), decreased albumin (malnutrition, chronic inflammation), elevated liver enzymes (CMV hepatitis, MAC, drug toxicity). Multiple abnormal findings may accompany on chest X-ray and CT, such as ground-glass opacity (PCP), nodules (MAC, tuberculosis, fungi), and pleural effusion.


8. Screening

The best approach is to diagnose HIV early, before reaching the AIDS stage that causes multiple infections. HIV screening is recommended not only for those with high-risk behavior but for a broad population.

HIV screening test

The current standard HIV screening test is the 4th-generation (combo) immunoassay, which simultaneously detects HIV-1/2 antibodies and the p24 antigen. This test shows positive results even within about 18–45 days after infection (window period), allowing earlier diagnosis than 3rd-generation antibody-only tests. When the screening test is positive, confirmation is by Western blot or HIV RNA PCR. The CDC recommends at least one HIV test for all adults aged 13–64, and recommends testing at least once a year for high-risk groups (multiple partners, injection drug use, MSM, etc.).

Immunological and virological monitoring

After HIV confirmation, the CD4+ T-cell count and HIV RNA viral load are measured regularly. The CD4 count is used as the criterion for starting chemoprophylaxis of opportunistic infections and for assessing immune status. The standard is measurement before ART initiation and 4–8 weeks after initiation, then at 3–6 month intervals. At a CD4 count below 200/μL, chemoprophylaxis for opportunistic infections (PCP prophylaxis) is started immediately.

Screening for opportunistic infections

Specific opportunistic infection screening tests are performed according to CD4 level. CD4 <200/μL: serum cryptococcal antigen test (recommended in some regions), chest X-ray (tuberculosis screening). CD4 <100/μL: CMV IgG (assessing risk of CMV exposure in seronegative patients), MAC blood culture (if symptomatic). In tuberculosis-endemic regions, the tuberculin test or interferon-gamma release assay (IGRA) is performed.


9. Diagnosis

Diagnosis of multiple-infection HIV disease includes confirmation of HIV infection and specific diagnosis of each opportunistic infection. The B20.7 code applies when two or more opportunistic infections are identified simultaneously or within a short period.

HIV confirmation

Confirmation by Western blot or HIV-1 RNA PCR after a positive 4th-generation combo test. Differentiating HIV-1 from HIV-2 is important for treatment planning, and HIV-2 has intrinsic resistance to NNRTIs.

Diagnostic methods by opportunistic infection

Pneumocystis pneumonia (PCP): identification of Pneumocystis cysts in bronchoalveolar lavage fluid (BAL) or induced sputum by Giemsa and Grocott-Gomori methenamine silver (GMS) staining. PCR has high sensitivity. Elevated serum β-D-glucan (adjunct to positive predictive value). Ground-glass opacity on high-resolution chest CT. Cryptococcal meningitis: serum and cerebrospinal fluid cryptococcal antigen (CrAg) test (sensitivity >95%), CSF India ink stain, culture. CMV retinitis: fundus examination (indirect ophthalmoscopy), blood CMV DNA PCR. Toxoplasma encephalitis: brain MRI (multiple ring-enhancing lesions), serum Toxoplasma IgG, clinical response to empirical treatment. MAC: blood or tissue culture (bone marrow, lymph node). Tuberculosis: sputum acid-fast bacilli smear and culture, PCR, chest CT.

Integrated evaluation of multiple infections

When multiple infection is suspected, systematic differential diagnosis is needed. While carrying out the specific diagnostic tests for each opportunistic infection simultaneously, treatment is prioritized in order of clinical likelihood. Tissue biopsy (lymph node, bone marrow, lung) can diagnose multiple pathogens at once and is useful for early identification of multiple infections.


10. Treatment

Treatment of multiple-infection HIV disease combines immune recovery by ART with specific anti-infective treatment for each opportunistic infection.

Antiretroviral therapy (ART)

Current WHO and DHHS guidelines recommend immediate initiation of ART in all HIV-infected individuals regardless of CD4 level. The goal of ART is to suppress HIV RNA to an undetectable level (<50 copies/mL) to promote CD4 recovery. Standard ART is a combination of two NRTIs + one integrase strand transfer inhibitor (INSTI) (e.g., tenofovir/emtricitabine + dolutegravir). With multiple infections, the timing of ART initiation (especially consider a 2–8 week delay with tuberculosis co-infection) and drug interactions (rifampin–INSTI/PI) must be considered.

Treatment by opportunistic infection

PCP: TMP-SMX (trimethoprim-sulfamethoxazole) 15–20 mg/kg/day (as TMP) for 21 days. With hypoxemia (PaO₂ <70 mmHg or A-a gradient >35 mmHg), add steroids (prednisolone 40 mg twice daily for 5 days → taper). Cryptococcal meningitis: induction therapy — amphotericin B + flucytosine for 2 weeks; consolidation therapy — fluconazole 400 mg/day for 8 weeks; maintenance therapy — fluconazole 200 mg/day. Therapeutic lumbar puncture if intracranial pressure is elevated. Toxoplasma encephalitis: pyrimethamine + sulfadiazine + leucovorin for 6 weeks, followed by maintenance therapy. CMV retinitis: ganciclovir (IV) or valganciclovir (oral) induction followed by maintenance. MAC: azithromycin + ethambutol (± rifabutin) long-term maintenance. In multiple infections, multiple anti-infective agents are used in combination and drug interactions must be managed closely.

Chemoprophylaxis

The standard is TMP-SMX at CD4 <200/μL (PCP prophylaxis), fluconazole at CD4 <100/μL (cryptococcal prophylaxis, in some regions), and weekly azithromycin at CD4 <50/μL (MAC prophylaxis). Once CD4 recovers above a certain level after ART, chemoprophylaxis can be stopped.


11. Prognosis

The prognosis of multiple-infection HIV disease has changed dramatically between before and after ART. Even in the ART era, short-term mortality remains high when multiple infections are diagnosed with an extremely low CD4.

Prognosis before ART

In the era without ART, median survival of patients with multiple infections at the AIDS stage was about 1–2 years, and median survival after a first episode of Pneumocystis pneumonia was about 9 months. The prognosis was even worse for severe opportunistic infections such as cryptococcal meningitis and CMV retinitis.

Prognosis after ART

In the ART era, life expectancy of HIV-infected individuals has approached that of the general population. When early diagnosis and early ART initiation have been achieved, cardiovascular disease, malignancy, and liver and kidney disease, rather than HIV infection itself, have become the leading causes of death. However, it has been reported that 3-month mortality reaches 15–30% when multiple infections occur in advanced AIDS with CD4 <50/μL. IRIS after ART initiation can worsen the clinical status in the short term but does not greatly affect the long-term prognosis.

Prognostic factors

The main prognostic determinants are nadir CD4, the timing of ART initiation, the type and severity of opportunistic infections, the patient's overall health status and comorbidities, and ART adherence. Even after reaching the AIDS stage, if CD4 is restored and sustained through ART, the risk of recurrence of AIDS-defining opportunistic infections can be greatly reduced.


12. Prevention

Prevention of multiple infections has two axes: prevention of HIV infection and prevention of immunosuppression after HIV infection (early ART initiation).

Primary prevention of HIV

Correct condom use, reducing the number of partners, and early treatment of sexually transmitted infections block sexual transmission. Pre-exposure prophylaxis (PrEP): taking TDF/FTC (tenofovir/emtricitabine) daily reduces the risk of HIV infection by more than 90%. Needle exchange programs and treatment of drug addiction are effective in injection drug users. Post-exposure prophylaxis (PEP): infection is prevented by starting ART within 72 hours after potential HIV exposure. To prevent vertical transmission, ART is given to pregnant women with HIV, and antiretroviral drugs are given during delivery and to the newborn.

Prevention of opportunistic infections

The most effective prevention of opportunistic infections is to keep the CD4 count high by starting ART early after HIV infection and continuing it. Chemoprophylaxis by CD4 level: TMP-SMX 1 tablet/day at CD4 <200/μL (prevention of PCP and toxoplasmosis), azithromycin 1,200 mg/week at CD4 <50/μL (MAC prevention). Tuberculosis preventive therapy (isoniazid for 6–12 months or the 3HP regimen) is given to HIV-infected individuals diagnosed with LTBI (latent tuberculosis infection). Food safety (drinking bottled water and eating cooked food to prevent toxoplasma and cryptosporidium), caution with animal contact, and avoiding live vaccines when immunosuppressed are recommended.


13. References

  1. UNAIDS. Global AIDS Update 2024: The Urgency of Now. UNAIDS. 2024. https://www.unaids.org/en/resources/documents/2024/global-aids-update-2024

  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. 2024. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv

  3. Masur H, Brooks JT, Benson CA, et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines. Clin Infect Dis. 2014;58(9):1308-1311. DOI: 10.1093/cid/ciu094. PMID: 24585567.

  4. Lundgren JD, Babiker AG, Gordin F, et al; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807. DOI: 10.1056/NEJMoa1506816. PMID: 26192873.

  5. WHO. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring. WHO. 2021. ISBN: 9789240031593.

  6. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014;384(9939):258-271. DOI: 10.1016/S0140-6736(14)60164-1. PMID: 24907868.

  7. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Recomm Rep. 2009;58(RR-4):1-207. PMID: 19357635.

  8. Korea Disease Control and Prevention Agency (KDCA). 2023 HIV/AIDS Notification Annual Report. Korea Disease Control and Prevention Agency. 2024. https://www.kdca.go.kr

  9. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830-839. DOI: 10.1056/NEJMoa1600693. PMID: 27424812.

  10. Danel C, Moh R, Gabillard D, et al; TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808-822. DOI: 10.1056/NEJMoa1507198. PMID: 26193126.